Pathogenesis of Theiler's virus-induced demyelinating disease

泰勒病毒引起的脱髓鞘病的发病机制

基本信息

  • 批准号:
    9093302
  • 负责人:
  • 金额:
    $ 23.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-02-01 至 2018-01-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): DA strain of Theiler's murine encephalomyelitis virus (TMEV) causes TMEV-induced demyelinating disease (TMEV-IDD), which serves as an experimental model of multiple sclerosis (MS): both diseases have similar immune-mediated demyelinating pathology. In contrast, GDVII strain of TMEV causes a fatal encephalomyelitis without demyelination or virus persistence. Both DA L and GDVII L protein block IFN-β transcription, however, they do so at different sites in the IRF-3 pathway. DA L, and therefore DA virus infection, blocks the activation of IRF-3, while GDVII L, and therefore GDVII virus infection (as well as infection by a mutant virus called DALGDVII, in which DA L is replaced by GDVII L), activates IRF-3, but blocks the binding of IRF-3 to the IFN-β promoter. Of note, activated IRF-3: is critical for IL-27 synthesis, which inhibits Th17 cells; decreases IL-17 secretion by CD4+ memory cells; is important in the differentiation of IL-10- secreting Tr1 cells, a regulatory T cell that can resolve inflammation and restore tolerance; negatively regulates granulocyte-macrophage-colony stimulating factor (GM-CSF) expression in T cells, which is important in mediating experimental allergic encephalomyelitis (EAE). Activated IRF-3 also interferes with production of IL- 12p40, a subunit of IL-12 and IL-23, preventing polarization of naïve T cells into proinflammatory Th1 cells (induced by IL-12) and Th17 cells (induced by IL-23). In the present proposal, we hypothesize that the activation or the failure of activation of IRF-3 (and the balance of IL-27/Th17) is important in the demyelination induced by TMEV, and in (partly) determining the two TMEV subgroup disease phenotypes. Antagonism of the IFN-β response because of a failure to activate IRF-3 may occur following infections with varied pathogens, and this may be the reason that the initiation of MS and/or an MS attack (or of another autoimmune disease) occurs after infection with these pathogens. A better understanding of these activities of the innate immune system in TMEV-IDD may clarify its pathogenesis and open up new therapeutic directions in MS.
 描述(由申请人提供):泰勒氏鼠脑脊髓炎病毒(TMEV)的DA毒株引起TMEV诱导的脱髓鞘疾病(TMEV-IDD),其用作多发性硬化症(MS)的实验模型:两种疾病具有相似的免疫介导的脱髓鞘病理学。相比之下,TMEV的GDVII株引起致命的脑脊髓炎,而没有脱髓鞘或病毒持续存在。DA L和GDVII L蛋白都阻断IFN-β转录,然而,它们在IRF-3途径中的不同位点这样做。DA L以及因此DA病毒感染阻断IRF-3的活化,而GDVII L以及因此GDVII病毒感染(以及被称为DALGDVII的突变病毒感染,其中DA L被GDVII L替代)活化IRF-3,但阻断IRF-3与IFN-β启动子的结合。值得注意的是,活化的IRF-3:对IL-27合成至关重要,其抑制Th 17细胞;减少CD 4+记忆细胞的IL-17分泌;在分泌IL-10的Tr 1细胞的分化中重要,Tr 1细胞是一种调节性T细胞,可以解决炎症和恢复耐受性;负调节T细胞中粒细胞-巨噬细胞-集落刺激因子(GM-CSF)的表达,其在介导实验性变态反应性脑脊髓炎(EAE)中是重要的。活化的IRF-3还干扰IL-12和IL-23亚基IL-12 p40的产生,阻止幼稚T细胞极化为促炎性Th 1细胞(由IL-12诱导)和Th 17细胞(由IL-23诱导)。在目前的建议中,我们假设IRF-3的激活或激活失败(和IL-27/Th 17的平衡)在TMEV诱导的脱髓鞘中是重要的,并在(部分)确定两个TMEV亚组疾病表型。由于无法激活IRF-3,IFN-β应答的拮抗作用可能在感染各种病原体后发生,这可能是MS和/或MS发作(或另一种自身免疫性疾病)在感染这些病原体后开始的原因。更好地了解TMEV-IDD先天免疫系统的这些活动可能会阐明其发病机制,并开辟MS新的治疗方向。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RAYMOND Philip ROOS其他文献

RAYMOND Philip ROOS的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RAYMOND Philip ROOS', 18)}}的其他基金

Guanabenz in the treatment of mutant SOD1 ALS mice
胍那苯治疗突变型 SOD1 ALS 小鼠
  • 批准号:
    8442820
  • 财政年份:
    2012
  • 资助金额:
    $ 23.7万
  • 项目类别:
Guanabenz in the treatment of mutant SOD1 ALS mice
胍那苯治疗突变型 SOD1 ALS 小鼠
  • 批准号:
    8280775
  • 财政年份:
    2012
  • 资助金额:
    $ 23.7万
  • 项目类别:
Single chain Fragments of variable regions in the treatment of Familial ALS
可变区单链片段治疗家族性肌萎缩侧索硬化症
  • 批准号:
    7904720
  • 财政年份:
    2010
  • 资助金额:
    $ 23.7万
  • 项目类别:
Single chain Fragments of variable regions in the treatment of Familial ALS
可变区单链片段治疗家族性肌萎缩侧索硬化症
  • 批准号:
    8049184
  • 财政年份:
    2010
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    8238678
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    8036079
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    7779486
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    8435565
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    8233407
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:
Preparing Trainees in Neurology and Neurosurgery for Academic Research Careers
为神经病学和神经外科学员的学术研究职业做好准备
  • 批准号:
    8574844
  • 财政年份:
    2009
  • 资助金额:
    $ 23.7万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 23.7万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 23.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了